Tharimmune, Inc.

Equities

THAR

US4327053090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-07 EDT			5-day change	1st Jan Change
5.2 ^USD	+1.76%		+9.58%	-31.89%

05-25	Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	CI
05-25	Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	CI

Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 08:31 am

Tharimmune, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 2.26 million compared to USD 2.69 million a year ago. Basic loss per share from continuing operations was USD 2.85 compared to USD 87.6 a year ago.

Latest news about Tharimmune, Inc.

Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	05-24	CI
Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	05-24	CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	05-24	CI
Tharimmune to Implement 1-for-15 Reverse Stock Split	05-22	MT
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	04-23	CI
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	02-20	CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	02-05	CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	01-29	CI
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease	12-11	MT
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	12-11	CI
Sector Update: Health Care Stocks Retreat in Late Afternoon	11-28	MT
Top Midday Decliners	11-28	MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	11-28	MT
Top Premarket Decliners	11-28	MT
Tharimmune Prices $10 Million Public Share Offering	11-28	MT
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	11-27	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	11-17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	11-17	MT
Tharimmune to Implement 1-for-25 Reverse Stock Split	11-17	MT
Tharimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Tharimmune, Inc. Announces Execution of an Exclusive Worldwide Licensing Agreement with Avior Inc. D/B/A Avior Bio, Llc ("Avior") to Develop, Market and Commercialize A Clinical-Stage Asset, Av104 (To Be Renamed Th104 and Hereinafter Referred to as Th104)	11-06	CI
Certain Warrants of Hillstream BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI
Certain Options of Hillstream BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI

Chart Tharimmune, Inc.

Duration

Period

More charts

Company Profile

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.2 USD

Average target price

75 USD

Spread / Average Target

+1,342.31%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THARIMMUNE, INC.	-31.89%	4.09M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs